Cytomorphologic fatures of intraductal salivary gland carcinoma: A multi‐institutional study of 13 FNA cases with histologic, molecular, and clinical correlations

2021 ◽  
Author(s):  
Kartik Viswanathan ◽  
Peter M. Sadow ◽  
Zahra Maleki ◽  
Michiya Nishino ◽  
Zubair W. Baloch ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Salivary Gland Carcinoma ◽  
Gland Carcinoma ◽  
Clinical Correlations

Boron neutron capture therapy for advanced salivary gland carcinoma in head and neck

2013 ◽  
Vol 19 (3) ◽  
pp. 437-444 ◽  
Author(s):  
Teruhito Aihara ◽  
Norimasa Morita ◽  
Nobuhiko Kamitani ◽  
Hiroaki Kumada ◽  
Koji Ono ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Head And Neck ◽  
Boron Neutron Capture Therapy ◽  
Neutron Capture ◽  
Neutron Capture Therapy ◽  
Salivary Gland Carcinoma ◽  
Boron Neutron Capture ◽  
Gland Carcinoma

Evaluation of pembrolizumab monotherapy in patients with salivary gland carcinoma in the phase 2 KEYNOTE-158 study

Oral Oncology ◽  
2021 ◽  
Vol 118 ◽  
pp. 9
Author(s):  
Caroline Even ◽  
Jean-Pierre Delord ◽  
Katharine A. Price ◽  
Kazuhiko Nakagawa ◽  
Do-Youn Oh ◽  
...  
Keyword(s):  
Salivary Gland ◽  
Phase 2 ◽  
Salivary Gland Carcinoma ◽  
Gland Carcinoma

scholarly journals Incidence and Prognostic Significance of PD-L1 Expression in High-Grade Salivary Gland Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Qigen Fang ◽  
Yao Wu ◽  
Wei Du ◽  
Xu Zhang ◽  
Defeng Chen
Keyword(s):  
Salivary Gland ◽  
Tumor Cells ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
Tumor Stage ◽  
Advanced Tumor Stage ◽  
High Grade ◽  
Salivary Gland Carcinoma ◽  
Gland Carcinoma ◽  
The Difference

ObjectivePD-L1 is one of the predictors of immunotherapy efficacy. Our goal was to analyze its expression and prognostic significance in high-grade salivary gland carcinoma (SGC).MethodsPD-L1 expression was evaluated using paraffin-embedded specimens from patients with surgically treated high-grade SGC, and it was scored by the tumor proportion score (TPS), combined positive score (CPS), and immune cell (IC) score. Associations between clinicopathological variables, disease-free survival (DFS), overall survival (OS) and PD-L1 expression were assessed.ResultsTPS≥1% occurred in 47 patients with an incidence of 43.1%, and it was significantly related to an advanced tumor stage. In patients with TPS<1%, TPS ranging from 1% to 20%, and TPS≥20%, the 5-year DFS rates were 36%, 26%, and 13%, respectively, and the difference was significant. In patients with TPS<1%, TPS ranging from 1% to 20%, and TPS≥20%, the 5-year OS rates were 49%, 24%, and 13%, respectively, and the difference was significant. CPS≥1 occurred in 87 patients with an incidence of 79.8%. IC scores of 0, 1, 2, and 3 were noted in 24 (22.0%), 37 (33.9%), 31 (28.4%), and 17 (15.6%) patients, respectively. Both CPS and IC scores had no impact on DFS or OS.ConclusionsThe expression of PD-L1 in tumor cells of high-grade SGCs was not uncommon, and it was significantly associated with tumor stage. PD-L1 expression in tumor cells rather than in immune cells indicated a poor prognosis.

Sign in / Sign up

Export Citation Format

Share Document